To query whether weight loss by incretin agonism would impact cancer outcomes in pre-clinical models, we studied the impact of medical weight loss on two deadly cancers including pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD) as either obesity-associated or obesity-independent cancers, respectively. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.